ArticleClinical kidney journal2025

Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.

Wenyan Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.